Effects of CYP2C19 and CYP2C9 Polymorphisms on the Efficacy and Plasma Concentration of Lacosamide in Pediatric Patients with Epilepsy in China

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2024 Dec 10

PMID 39658609

Authors

Ting Zhao

Hong-Jian Li

Hui-Lan Zhang

Jing Yu

Jie Feng

Long Cui

Ke-Fang Sun

Yan Sun

Lu-Hai Yu

Affiliations

Soon will be listed here.

Abstract

Conclusion: LCM plasma concentrations were strongly associated with its clinical efficacy and toxicity. CYP2C19 polymorphisms affect the plasma concentration and treatment efficacy in pediatric patients with epilepsy. CYP2C19 PMs with two no-function alleles are likely to have higher LCM plasma concentrations.

What Is Known: • LCM is metabolized by CYP2C19, CYP2C9, and CYP3A4 into pharmacologically inactive O-desmethyl-lacosamide; it primarily undergoes renal elimination. • Plasma LCM concentrations in patients treated with the recommended dose vary widely between and within individuals variability.

What Is New: • CYP2C19 polymorphisms affect the plasma concentration and treatment efficacy in Chinese pediatric patients with epilepsy. • CYP2C19 PMs with two no-function alleles are likely to have higher plasma LCM concentrations.

References

Moshe S, Perucca E, Ryvlin P, Tomson T . Epilepsy: new advances. Lancet. 2014; 385(9971):884-98. DOI: 10.1016/S0140-6736(14)60456-6. View

Vossler D, Knake S, OBrien T, Watanabe M, Brock M, Steiniger-Brach B . Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2020; 91(10):1067-1075. PMC: 7509528. DOI: 10.1136/jnnp-2020-323524. View

Arabi M, Alsaadi T, Nasreddine W, Al-Hashel J, Dirani M, Beydoun A . Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region. Epilepsy Behav. 2018; 84:118-121. DOI: 10.1016/j.yebeh.2018.04.020. View

Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain N . Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav. 2015; 52(Pt A):119-27. DOI: 10.1016/j.yebeh.2015.09.006. View

Zadeh W, Escartin A, Byrnes W, Tennigkeit F, Borghs S, Li T . Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial. Seizure. 2015; 31:72-9. DOI: 10.1016/j.seizure.2015.07.001. View

Zhao T, Li H, Ma L, Feng J, Wang T, Yu J . Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China. Epilepsy Behav. 2021; 117:107814. DOI: 10.1016/j.yebeh.2021.107814. View

Zhao T, Li H, Zhang H, Yu J, Feng J, Wang T . Twelve-Month Efficacy of Lacosamide Monotherapy at Maximal Dose and Tolerability for Epilepsy Treatment in Pediatric Patients: Real-World Clinical Experience. Pediatr Neurol. 2023; 142:23-30. DOI: 10.1016/j.pediatrneurol.2023.01.018. View

Zhao T, Yu L, Zhang H, Yu J, Feng J, Wang T . Long-term effectiveness and safety of lacosamide as adjunctive therapy in children and adolescents with refractory epilepsy: a real-world study. BMC Pediatr. 2023; 23(1):249. PMC: 10199619. DOI: 10.1186/s12887-023-04039-5. View

Zhao T, Li H, Zhang H, Yu J, Feng J, Wang T . Therapeutic Drug Monitoring of Lacosamide in Chinese Pediatric Patients with Epilepsy: Efficacy and Factors Influencing the Plasma Concentration. Eur J Drug Metab Pharmacokinet. 2022; 48(1):41-49. DOI: 10.1007/s13318-022-00808-2. View

10.

Contin M, Albani F, Riva R, Candela C, Mohamed S, Baruzzi A . Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013; 35(6):849-52. DOI: 10.1097/FTD.0b013e318290eacc. View

11.

Yamamoto Y, Terada K, Araki Y, Fukushima Y, Imai K, Kagawa Y . Therapeutic Monitoring of Lacosamide in Japanese Patients With Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range. Ther Drug Monit. 2020; 42(5):754-759. DOI: 10.1097/FTD.0000000000000764. View

12.

Cawello W, Stockis A, Andreas J, Dimova S . Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Ann N Y Acad Sci. 2014; 1329:18-32. DOI: 10.1111/nyas.12513. View

13.

Cawello W, Boekens H, Bonn R . Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet. 2012; 37(4):241-8. DOI: 10.1007/s13318-012-0093-x. View

15.

May T, Helmer R, Bien C, Brandt C . Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages. Ther Drug Monit. 2018; 40(5):620-627. DOI: 10.1097/FTD.0000000000000538. View

16.

Scheffer I, Berkovic S, Capovilla G, Connolly M, French J, Guilhoto L . ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4):512-521. PMC: 5386840. DOI: 10.1111/epi.13709. View

17.

Shi Y, He L . SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15(2):97-8. DOI: 10.1038/sj.cr.7290272. View

18.

Svendsen T, Brodtkorb E, Baftiu A, Burns M, Johannessen S, Johannessen Landmark C . Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability. Neurochem Res. 2017; 42(7):2077-2083. DOI: 10.1007/s11064-017-2234-8. View

19.

Cawello W . Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015; 54(9):901-14. DOI: 10.1007/s40262-015-0276-0. View

20.

Markoula S, Teotonio R, Ratnaraj N, Duncan J, Sander J, Patsalos P . Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit. 2014; 36(4):494-8. DOI: 10.1097/FTD.0000000000000051. View

21.

Schaefer C, Cawello W, Waitzinger J, Elshoff J . Effect of age and sex on lacosamide pharmacokinetics in healthy adult subjects and adults with focal epilepsy. Clin Drug Investig. 2015; 35(4):255-65. DOI: 10.1007/s40261-015-0277-7. View